[The Relationship between the Expressions of CD33 and CD13 and the Prognosis of Patients with Multiple Myeloma].

Objective: To investigate the expressions of CD33 and CD13 in newly diagnosed multiple myeloma (MM) patients and its relationship with prognosis.

Methods: It was retrospectively observed that the expression of CD33 and CD13 in 121 MM patients who were newly diagnosed from January 2014 to January 2020, and the relationship between the expressions of CD33 and CD13 and patients prognosis was analyzed.

Results: Among the 121 newly diagnosed MM patients, there were 30 patients (24.8%) in the CD33 group and 12 patients (9.9%) in the CD13 group. Kaplan-Meier analysis showed that, compared with the CD33 group, the progression-free survival (PFS) time and overall survival (OS) time were significantly shortened in MM patients in CD33 group (PFS 17.5 vs 23 months, P=0.000; OS 18.5 vs 25 months, P=0.000); and the PFS time and OS time of MM patients in the CD13 group were also significantly shortened than those in CD13 group (PFS 21 vs 22 months, P=0.012; OS 25 vs 26 months, P=0.006). Cox regression analysis showed that CD33 and CD13 were independent adverse prognostic factors in MM patients (CD33: P=0.000;CD13: P=0.003).

Conclusion: CD33 and CD13 are prognostic risk factors in patients with MM.